Growth Metrics

Halozyme Therapeutics (HALO) Goodwill (2022 - 2025)

Halozyme Therapeutics (HALO) has disclosed Goodwill for 1 consecutive years, with $416.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Goodwill changed N/A to $416.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $416.8 million, a N/A change, with the full-year FY2024 number at $416.8 million, changed N/A from a year prior.
  • Goodwill was $416.8 million for Q4 2024 at Halozyme Therapeutics.
  • In the past five years, Goodwill ranged from a high of $416.8 million in Q4 2024 to a low of $416.8 million in Q4 2024.